利妥昔单抗时代年轻套细胞淋巴瘤患者的生存结局
该回顾性研究纳入2000至2015年65岁及以下初诊套细胞淋巴瘤患者,来自25个医疗中心,共1029例符合标准。中位随访76个月,中位无进展生存期(PFS)和总生存期(OS)分别为62和139个月。倾向评分加权分析后,自体造血干细胞移植(AHCT)巩固治疗与改善PFS相关(HR 0.70),但与OS改善无关(HR 0.87)。
要点
- 在年轻、适合移植的套细胞淋巴瘤患者中,AHCT巩固治疗与显著改善的PFS相关。
- 倾向评分加权分析后,AHCT与OS改善无显著关联。
- 作者认为,在年轻、体能状态良好的患者中,AHCT巩固可能改善PFS。
核心结论
- 在年轻、适合移植的套细胞淋巴瘤患者中,诱导化疗后AHCT巩固与显著改善的PFS相关,但倾向评分加权分析后未显示OS改善。
- 作者认为,在回顾性分析的局限性内,研究结果提示在年轻、体能状态良好的患者中,AHCT巩固可能改善PFS。
研究设计与样本
- 回顾性研究,纳入2000年至2015年间在25个医疗中心初诊的65岁及以下适合移植的套细胞淋巴瘤成人患者。
- 共收集1254例患者数据,其中1029例符合纳入标准。
- 主要目标是评估AHCT巩固是否改善PFS,次要目标是评估OS。
- 采用Cox多变量回归分析和倾向评分加权(PSW)分析。
主要发现
- 中位随访时间为76个月,中位PFS和OS分别为62个月和139个月。
- 未调整分析中,AHCT与改善的PFS相关(有AHCT组75个月 vs 无AHCT组44个月,P < .01)。
- 未调整分析中,AHCT与改善的OS相关(有AHCT组147个月 vs 无AHCT组115个月,P < .05)。
- 多变量回归分析中,AHCT与改善的PFS相关(HR 0.54;95% CI 0.44-0.66;P < .01),OS有改善趋势(HR 0.77;95% CI 0.59-1.01;P = .06)。
- 倾向评分加权分析后,AHCT仍与改善的PFS相关(HR 0.70;95% CI 0.59-0.84;P < .05),但与OS改善无关(HR 0.87;95% CI 0.69-1.1;P = .2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出研究为回顾性分析,并说明结论受回顾性分析局限性约束。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS: We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed. RESULTS: Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION: In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
引用
- Gerson JN, Handorf E, Villa D, et al. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol. 2019. PMID: 30615550. doi:10.1200/JCO.18.00690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。